http://www.twitter.comTwitter is a service for friends, family, and co-workers to communicate and stay connected through the exchange of quick, frequent answers to one simple question: What are you doing?
View Older Stories View More Recent Stories
-
Halozyme Announces Takeda Received Regulatory Approval for HYQVIA® 10% Subcutaneous Injection Set with ENHANZE® in Japan for Patients with Agammaglobulinemia or Hypogammaglobulinemia
-
Halozyme Therapeutics (HALO) Announces argenx's VYDURA with ENHANZE was Granted Regulatory Approval in Japan
-
Halozyme Announces argenx's VYDURA with ENHANZE® was Granted Regulatory Approval in Japan for Chronic Inflammatory Demyelinating Polyneuropathy
-
Halozyme (HALO) Announces FDA Approval of Bristol Myers Squibb's Opdivo Qvantig™ with ENHANZE® for Subcutaneous Use in Most Previously Approved Adult Solid Tumor Opdivo® (nivolumab) Indications
-
Halozyme Announces FDA Approval of Bristol Myers Squibb's Opdivo Qvantig™ with ENHANZE® for Subcutaneous Use in Most Previously Approved Adult Solid Tumor Opdivo® (nivolumab) Indications
-
Halozyme to Present at Upcoming Investor Conferences
-
Halozyme Therapeutics (HALO) Withdraws Proposal to Acquire Evotec (EVO) Following Evotec's Unwillingness to Engage in Discussions
-
Halozyme Withdraws Proposal to Acquire Evotec Following Evotec's Unwillingness to Engage in Discussions
-
Halozyme Therapeutics (HALO) Provides Update on Non-Binding Proposal to Combine with Evotec (EVO)
-
Halozyme Provides Update on Non-Binding Proposal to Combine with Evotec
-
Halozyme Therapeutics (HALO) Confirms Proposal to Combine with Evotec (EVO) for €11.00 Per Share in an All-Cash Transaction
-
Halozyme Confirms Proposal to Combine with Evotec for €11.00 Per Share in an All-Cash Transaction
-
HALOZYME REPORTS THIRD QUARTER 2024 FINANCIAL AND OPERATING RESULTS
-
Halozyme Therapeutics (HALO) Provides Update on Licensee Co-formulation Patent Hearing in Europe
-
HALOZYME PROVIDES UPDATE ON LICENSEE CO-FORMULATION PATENT HEARING IN EUROPE
-
Halozyme to Report Third Quarter 2024 Financial and Operating Results
-
Halozyme Therapeutics (HALO) Announces Expansion of Global Collaboration and License Agreement with argenx for ENHANZE
-
Halozyme Announces Expansion of Global Collaboration and License Agreement with argenx for ENHANZE®
-
Halozyme Therapeutics (HALO) Announces FDA Approval of Roche's Subcutaneous OCREVUS ZUNOVO with ENHANZE
-
Halozyme Announces FDA Approval of Roche's Subcutaneous OCREVUS ZUNOVO™ with ENHANZE® for People with Relapsing and Primary Progressive Multiple Sclerosis
-
Halozyme Announces FDA Approval of Roche's Tecentriq Hybreza™ With ENHANZE® for Multiple Types of Cancer
-
Halozyme to Present at Upcoming Investor Conferences
-
HALOZYME REPORTS SECOND QUARTER 2024 FINANCIAL AND OPERATING RESULTS
-
Halozyme to Report Second Quarter 2024 Financial and Operating Results
-
Halozyme Announces Roche's OCREVUS® SC with ENHANZE® Receives European Commission Approval for Relapsing and Primary Progressive Multiple Sclerosis
-
Halozyme Announces argenx Receives FDA Approval for VYVGART® Hytrulo Co-Formulated with ENHANZE® for Chronic Inflammatory Demyelinating Polyneuropathy
-
Halozyme Therapeutics (HALO) Raises Full Year 2024 Financial Guidance and Updates 5-Year Financial Outlook
-
Halozyme Raises Full Year 2024 Financial Guidance and Updates 5-Year Financial Outlook
-
Halozyme Therapeutics (HALO) Receives EU Patent for ENHANZE
-
Halozyme Announces Issuance of New European Patent for ENHANZE® Drug Delivery Platform
-
Halozyme to Participate in the Goldman Sachs 45th Annual Global Healthcare Conference
-
Halozyme Therapeutics (HALO) Announces Bristol Myers Squibb (BMY) Received Updated Action Date from FDA for Subcutaneous Nivolumab Co-Formulated with ENHANZE
-
Halozyme Announces Bristol Myers Squibb Received Updated Action Date from the U.S. Food and Drug Administration for Subcutaneous Nivolumab Co-Formulated with ENHANZE®
-
Halozyme to Participate in Upcoming Investor Conferences
-
HALOZYME REPORTS FIRST QUARTER 2024 FINANCIAL AND OPERATING RESULTS
-
Mahesh Krishnan Elected to Halozyme's Board of Directors
-
Halozyme to Report First Quarter 2024 Financial and Operating Results
-
Halozyme to Participate in Upcoming Investor Conferences
-
HALOZYME REPORTS FOURTH QUARTER AND FULL YEAR 2023 FINANCIAL AND OPERATING RESULTS
-
Halozyme To Report Fourth Quarter and Full Year 2023 Financial and Operating Results
-
Halozyme Announces Takeda Received European Commission Approval for HYQVIA® Co-formulated with ENHANZE® as Maintenance Therapy for Chronic Inflammatory Demyelinating Polyneuropathy (CIDP)
-
Halozyme (HALO) Announces argenx Received Approval in Japan for VYVDURA Co-Formulated with ENHANZE for gMG
-
Halozyme Announces argenx Received Approval in Japan for VYVDURA® (efgartigimod alfa and hyaluronidase-qvfc) Co-Formulated with ENHANZE® for Generalized Myasthenia Gravis
-
Halozyme (HALO) Announces Takeda (TAK) Receives FDA Approval for HYQVIA Co-formulated with ENHANZE as Maintenance Therapy in Adults with CIDP
-
Halozyme Announces Takeda Receives FDA Approval for HYQVIA® Co-formulated with ENHANZE® as Maintenance Therapy in Adults with Chronic Inflammatory Demyelinating Polyneuropathy (CIDP)
-
Halozyme (HALO) Announces Roche Receives EU Approval of Tecentriq SC with ENHANZE
-
Halozyme Announces Roche Receives European Commission Approval of Tecentriq® SC with ENHANZE® Representing the EU's First Subcutaneous PD-(L)1 Cancer Immunotherapy for Multiple Cancer Types
-
Halozyme to Host Investor Business Forum and Long-Term Outlook Call
-
Halozyme to Present at Upcoming Investor Conferences
-
Halozyme Therapeutics (HALO) Announces argenx Receives EU Approval of VYVGART SC with ENHANZE for Generalized Myasthenia Gravis
